The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 26, 2019

Filed:

Sep. 23, 2015
Applicants:

Jesus Manuel Perez, Orlando, FL (US);

Atul Asati, Orlando, FL (US);

Santimukul Santra, Orlando, FL (US);

Charalambos Kaittanis, New York, NY (US);

Inventors:

Jesus Manuel Perez, Orlando, FL (US);

Atul Asati, Orlando, FL (US);

Santimukul Santra, Orlando, FL (US);

Charalambos Kaittanis, New York, NY (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/50 (2006.01); A61K 33/24 (2006.01); A61K 9/51 (2006.01);
U.S. Cl.
CPC ...
A61K 33/24 (2013.01); A61K 9/5138 (2013.01); A61K 9/5161 (2013.01);
Abstract

Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines. In contrast, minimal toxicity is observed when they localize into the cytoplasm or do not enter the cells.


Find Patent Forward Citations

Loading…